The current coronavirus pandemic, COVID-19, has changed our daily lives in the blink of an eye. It has also brought widespread attention back to how the health care system and market dynamics impact how care is...
The current coronavirus pandemic, COVID-19, has changed our daily lives in the blink of an eye. It has also brought widespread attention back to how the health care system and market dynamics impact how care is...
In this series, we speak with cancer care practitioners about how pathways are being used in their practices, how they are being applied in a particular disease state, and what challenges remain for treatment...
In this series, we speak with cancer care practitioners about how pathways are being used in their practices, how they are being applied in a particular disease state, and what challenges remain for treatment...
Oncology is changing rapidly as models of care and reimbursement evolve. We have seen this firsthand with the rapid expansion of telehealth services to combat the COVID-19 (coronavirus) pandemic.
This challenge to...
Oncology is changing rapidly as models of care and reimbursement evolve. We have seen this firsthand with the rapid expansion of telehealth services to combat the COVID-19 (coronavirus) pandemic.
This challenge to...
As a community-spread disease, coronavirus 2019 shows us the importance of community—from global, national, state, local, workplace, and individual perspectives.
On March 11, 2020, World Health Organization...
As a community-spread disease, coronavirus 2019 shows us the importance of community—from global, national, state, local, workplace, and individual perspectives.
On March 11, 2020, World Health Organization...
A recent announcement that new biotech start-up, EQRx plans to launch “equivalars,” alternatives to a number of currently patented costly drugs at far lower price points, introduces another disruptive solution...
A recent announcement that new biotech start-up, EQRx plans to launch “equivalars,” alternatives to a number of currently patented costly drugs at far lower price points, introduces another disruptive solution...
Craig Ornstein, PhD, MA; Jamey Hardesty, MPH; Richard G. Stefanacci, DO, MGH, MBA, AGSF, CMD; Matthew Pakizegee, PharmD, MS; Uttama Rath, PhD, MS
Inclusion of oncology biosimilars in clinical pathways is one approach to reducing costs in this therapeutic area without compromising outcomes for cancer patients. There are currently eight Food and Drug...
Inclusion of oncology biosimilars in clinical pathways is one approach to reducing costs in this therapeutic area without compromising outcomes for cancer patients. There are currently eight Food and Drug...
This section called “CME Corner,” highlights, when available, relevant continuing medical education (CME) opportunities deemed to be of use to readers. Articles include an overview of a specific area where key...
This section called “CME Corner,” highlights, when available, relevant continuing medical education (CME) opportunities deemed to be of use to readers. Articles include an overview of a specific area where key...
Ajeet Gajra, MD, FACP; Ting-Chun Yeh, PhD; Chadi Nabhan, MD, MBA, FACP; Yolaine J. Jeune-Smith, PhD; Bruce A. Feinberg, DO; Andrew J. Klink, PhD, MPH; Bela Bapat, MS
Abstract: In the era of value-based care and constrained resources, oncology practices are increasingly employing advanced practice providers (APPs) to improve practice workflow, increase efficiency, and enable...
Abstract: In the era of value-based care and constrained resources, oncology practices are increasingly employing advanced practice providers (APPs) to improve practice workflow, increase efficiency, and enable...
Abstract: A multidisciplinary team at ChristianaCare, headquartered in Wilmington, DE, designed a comprehensive pathway utilizing an internally developed predictive model to proactively reduce oncology...
Abstract: A multidisciplinary team at ChristianaCare, headquartered in Wilmington, DE, designed a comprehensive pathway utilizing an internally developed predictive model to proactively reduce oncology...
Edward Arrowsmith, MD; Vishnukamal Golla, MD, MPH; Rhonda Henschel, MBA; Andrew Hertler, MD, FACP; David Jackman, MD; Gordon Kuntz; Olaf Lodbrok, MS, MBA; Carole Tremonti, RN, MBA; Lalan Wilfong, MD
The Predictable Cost of Care Working Group developed a model that can be used by various entities evaluating the impact of treatment on the total cost of care.
The Predictable Cost of Care Working Group developed a model that can be used by various entities evaluating the impact of treatment on the total cost of care.
Edward Arrowsmith, MD; Vishnukamal Golla, MD, MPH; Rhonda Henschel, MBA; Andrew Hertler, MD, FACP; David Jackman, MD; Gordon Kuntz; Olaf Lodbrok, MS, MBA; Carole Tremonti, RN, MBA; Lalan Wilfong, MD
The Predictable Cost of Care Working Group developed a model that can be used by various entities evaluating the impact of treatment on the total cost of care.
The Predictable Cost of Care Working Group developed a model that can be used by various entities evaluating the impact of treatment on the total cost of care.
Robin T. Zon, MD, FACP, FASCO; Gordon Kuntz; Winston Wong, PharmD
The Journal of Clinical Pathways convened the 2021 Care Pathways Working Group to identify and reconcile the different pathway drivers for each stakeholder now and five years into the future, creating a framework tool based on oncology care...
The Journal of Clinical Pathways convened the 2021 Care Pathways Working Group to identify and reconcile the different pathway drivers for each stakeholder now and five years into the future, creating a framework tool based on oncology care...